Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Non-Interventional Study on the Tolerability and Efficacy of IVIG (NCT02303093) | Octapharma | 2011-08-01 |
Track Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG automatically
Every clearance here is in the API, with alerts when new ones post.